Dr. Raza Bokhari reports

MEDICUS PHARMA LTD. APPOINTS FAISAL MEHMUD, MD, MRCP AS CHIEF MEDICAL OFFICER

Medicus Pharma Ltd. has appointed Dr. Faisal Mehmud, MD, as chief medical officer.

"We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, executive chairman and chief executive officer. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high-impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvable doxorubicin-containing microneedle array (D-MNA) to treat non-melanoma skin cancer, especially basal cell carcinoma."

Dr. Mehmud brings over 20 years of global experience as a senior medical executive in clinical development, medical affairs and drug safety across various therapeutic areas, including oncology, hematology, rare diseases and primary care. He has played a central role in multiple successful launches of new medicines, and has spearheaded innovative global medical life cycle management strategies, including for small molecules, antibodies, cell therapies and cytotoxic chemotherapies. His expertise encompasses late-phase development, product launch and the seamless integration of new therapies into treatment pathways, all with a focus on improving patient outcomes through forward-thinking clinical development plans. Dr. Mehmud's career includes senior roles at leading pharmaceutical companies, such as Sanofi, Novartis, Bristol Myers Squibb, Pfizer Inc. and GlaxoSmithKline based in London, Paris and Philadelphia.

Most recently, Dr. Mehmud was the senior vice-president, data generation and scientific communications in worldwide global medical affairs, at GlaxoSmithKline, which included leadership of medical affairs sponsored and supported by interventional and non-interventional clinical trials. Before GSK, Dr. Mehmud was with Pfizer, where he served in various roles, including as vice-president and worldwide medical franchise head for precision medicine and early oncology development, advancing the precision medicine oncology portfolio in a variety of tumor types, and supporting early-stage oncology projects moving from early clinical development to full development and market readiness, effectively bridging scientific innovation with commercial strategy.

Dr. Mehmud has also held leadership roles at Bristol Myers Squibb, including as vice-president in global drug safety, where he oversaw the safety risk management of complex therapies, including antibody-based treatments and cellular therapies.

Dr. Mehmud completed a medical degree from the University of Cambridge, as well as diplomas in internal medicine and pharmaceutical medicine from the Royal College of Physicians, and holds a medical licence with the United Kingdom General Medical Council.

The company also announced the promotion of Edward J. Brennan, MD, FACS, to chief scientific officer and head of the research and development program. Dr. Brennan, who was mostly recently the company's chief medical officer, is a veteran pharmaceutical industry leader with extensive experience in all phases of clinical development across multiple therapeutics areas.

"Dr. Brennan, as a co-founder of the company, has been instrumental in identifying our lead asset D-MNA and designing the clinical development program to position us to not only become the first-in-class but also the best-in-class novel therapeutic alternative to treat BCC," stated Dr. Bokhari. "Ed is an accomplished biopharmaceutical executive, and his elevation to the role of chief scientific officer is very timely as we strengthen our executive team and gallop forward our D-MNA phase 2 study."

Dr. Brennan has over 30 years of drug development experience. He has held senior medical leadership roles at major companies, including Wyeth, GlaxoSmithKline and IndiPharm. As medical director at Wyeth and GSK, Dr. Brennan led clinical development programs that resulted in 10 Food and Drug Administration drug approvals. He oversaw teams responsible for all phases of clinical research, as well as interactions with regulatory authorities. His therapeutic expertise includes immunology, oncology, women's health and genetic diseases. Before industry roles, Dr. Brennan practised medicine as a general surgeon.

Dr. Brennan received his undergraduate bachelor of science degree in pharmacy from Philadelphia College of Pharmacy and Science. He went on to study medicine at the Royal College of Surgeons in Ireland before receiving his medical degree from Temple University School of Medicine.

About Medicus Pharma Ltd.

Medicus is a biotech/life science company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets.

SkinJect Inc., a wholly owned subsidiary of Medicus, is a development-stage, life science company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumour cells. The company completed a phase 1 safety and tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability. The study also describes the efficacy of the investigational product D-MNA, with six participants experiencing complete response on histological examination of the resected lesion. The company submitted a phase 2 investigational new drug clinical protocol to the FDA in January, 2024, for a randomized, controlled, double-blind, multicentre clinical study (SKNJCT-003) that is expected to randomize up to 60 patients. The study is designed to evaluate the efficacy of two doses of two-dose levels (100 and 200 micrograms) of D-MNA compared with placebo (P-MNA) in subjects with nodular BCC. Patient recruitment is currently under way in nine sites across the United States.

We seek Safe Harbor.